MyVax Cancer Vaccine Failure Could Be Due To Active Comparator – Genitope
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A failed primary endpoint for Genitope's Phase III trial of follicular non-Hodgkin's lymphoma vaccine MyVax was due to a comparator group that was found to be active, the company said. The firm announced in a Dec. 20 conference call that its lead drug candidate MyVax elicited an immune response in just 40 percent of patients enrolled in the trial and failed to meet its primary endpoint of statistically significant progression-free survival compared to the control group
You may also be interested in...
R&D IN BRIEF
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief
R&D IN BRIEF
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief
Therapeutic Vaccine Trials Should Focus More On Patient Response – Study
A paradigm shift is needed in the field of therapeutic cancer vaccine trials that would evaluate patient response rather than tumor response, according to an analysis of prostate cancer vaccine trials in the July 1 issue of Clinical Cancer Research.